EU/3/18/2070
Table of contents
About
On 26 October 2018, orphan designation (EU/3/18/2070) was granted by the European Commission to Accelsiors CRO and Consultancy Services Ltd, Hungary, for (6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid (also known as lenabasum) for the treatment of dermatomyositis.
The sponsorship was transferred to Pharma Gateway AB, Sweden, in July 2020.
Key facts
Active substance |
(6aR,10aR)-3-(1,1-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid
|
Disease / condition |
Treatment of dermatomyositis
|
Outcome |
Positive
|
EU designation number |
EU/3/18/2070
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Pharma Gateway AB
Johanneslundsvägen 2
Hammarby
194 61 Upplands Väsby
Stockholms Lan
Sweden
Tel. +46 8 590 778 00
E-mail: info@pharmagateway.eu
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.